Hikma will acquire parts of Xellia's US finished dosage form business and assets. According to its statement this will ...
Hikma Pharmaceuticals PLC, which is headquartered in London, plans to acquire parts of Xellia Pharmaceuticals' finished dosage form business and assets, including a commercial portfolio and ...
Indian drugmaker Hikma has agreed in principle to a $150 million settlement to resolve lawsuits claiming that it contributed to the opioid crisis in the US, which could allow it to put the ...